You are here
Vertex Presents Data at the North American Cystic Fibrosis Conference (NACFC)
Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis
October 18, 2018
Today we announced that eight scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 32nd North American Cystic Fibrosis Conference taking place October 18-20, 2018 in Denver. Key highlights include presentations of Phase 2 data evaluating clinical safety and efficacy as well as in vitro data of two investigational triple combination regimens (VX-659, tezacaftor and ivacaftor; VX-445, tezacaftor and ivacaftor) in patients with one F508del mutation and one minimal function mutation (F508del/Min) and in patients with two F508del mutations (F508del/F508del), as well as in once-daily investigational triple combination regimens (VX-659, tezacaftor and VX-561; VX-445, tezacaftor and VX-561) in F508del/Min patients. Data from these studies were also published online today in The New England Journal of Medicine.